Editorial Podcasts

In episode 102, Mike Devoy, chief medical officer of Bayer, also executive vice president of medical affairs and pharmacovigilance for Bayer’s Pharmaceuticals Division, discusses how innovation, including the digitalization of healthcare delivery, and breakthrough technologies can help people make the most out of the longer lives they’re living today.

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.

Bill Sibold, executive vice president and head of Sanofi Genzyme, talks about his work in specialty care over the past 10 years and what makes it unique.

Giacomo Chiesi, Head of Global Rare Diseases at the Chiesi Group, discusses what it has been like growing up around pharma, and how he’s turned a family passion into his own dedicated career path.

Mike Ward, Global Head of Thought Leadership in the Decision Resources Group at Clarivate, goes behind the numbers of our 2022 pipeline report and provides some interesting insights from the report provided by his company.

Tim Whitten, CEO and president of Taiho Oncology, discusses how innovative thinking—from developing new therapies to creating a podcast for employees during COVID—has played an important role in his professional journey.

Jeff Stoll, US Life Sciences Strategy Leader at KPM, talks about some of the highlights from KPMG’s recent Global Pharma CEO Outlook report.

Amie Krause, Senior Vice President and Chief People Officer, and Kristin Yarema, Chief Commercial Officer, of Atara Biotherapeutics, talk about gender diversity in the c-suite and how that can benefit a company both internally and externally.

Michael Petroutsas, Senior Vice President and Head of GSK’s US Oncology Business Unit, talks about how his background has taught him the importance of connecting with patients on their level and how he brings that mentality to GSK.

Dr. Michael Henderson, chief business officer of BridgeBio Pharma, and one of Pharm Exec’s 2021 Emerging Pharma Leaders, discusses how his company goes beyond the traditional “hand off” approach between academia and industry, and looks to partner with institutions early on to fill important voids in drug development.

Dr. Edith Perez, Chief Medical Officer of Bolt Biotherapeutics, discusses how she approaches drug development in oncology, and what she contributes outside of work to help raise awareness for cancer.

Audrey Greenberg, co-founder and executive managing director of the Center for Breakthrough Medicines and Discovery Labs, discusses how cell and gene therapy has turned Philadelphia into Cellicon Valley, and how her organization is playing a role in that growth even beyond the city’s borders.

Yan Chen, CEO of Elpis Biopharmaceuticals, talks about how she transitioned her career from scientist to CEO and what that has entailed.

Arthur Kuan, CEO of CG Oncology, talks about the present and future of bladder cancer therapies, and how he’s committed to making a difference.

Emma Chaffin, vice president and country head of Galapagos UK, discusses how her personal journey with cancer put a spin on her life, including her career in pharma.

Teresa Bitetti, President of Takeda Pharmaceuticals’ Global Oncology Business Unit, talks about her experience as a leader in the oncology space and what that entails in today’s environment.

Judy Stewart, head of US vaccines at GSK, talks about the effects of people missing their recommended vaccinations during the pandemic and the importance of delivering a message of value for vaccines.

Mike Starich, CEO of Orion Talent, and Dr. Armand Balboni, CEO of Appili Therapeutics, talk about hiring veterans for roles in pharma, and how the industry can capitalize on their unique qualifications.

Sandor Schoichet, an independent advisor and director of Meridian Management Consultants based in San Francisco, and Thomas Scheiwiller, an independent advisor and board member based in Zurich, talk about integrating environmental, social, and governance, or ESG, issues into biopharma business planning, and communicating with capital investors about these areas.

Dr. Michele Cleary, CEO of the Mark Foundation for Cancer Research, discusses how the foundation has navigated COVID to help keep critical cancer research going throughout the pandemic.

John Furey, CEO of Imvax and an Editorial Advisory Board member for Pharm Exec, discusses some leadership principles he learned while playing rugby as a young man in Ireland, and how those tenets can translate to the C-suite.

Uche Iloeje, Vice President medical affairs Mirdametenib at SpringWorks Therapeutics, shares his experience after he became stranded in Nigeria for five months and the valuable leadership lessons he learned.

Paul Shawah, Executive Vice President of Strategy at Veeva Systems, looks back at the past year of the pandemic to see the digital transformation of pharma’s interaction with healthcare professionals.

Kevin Buckley, founder of Torrey Pines Law Group, and Neil Thompson, a patent agent with the firm, discuss IP strategy as it relates to pharma and artificial intelligence.

Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, talks about the effects of COVID on worldwide biomanufacturing, and what the repatriation of pharma could look like.

Scott Nawrocki, managing director of digital investigations and cyber defense at Nardello & Co., discusses cybersecurity in pharma, including topics from prevention to crisis management.

Editorial Director, Lisa Henderson; European and online editor, Julian Upton; Senior Editor, Elaine Quilici ;and Assistant Editors of Pharmaceutical Executive, Miranda Schmalfuhs and Andy Studna, discuss some exciting industry trends for 2021, which they recently wrote for the January issue.

Gregg Beloff, co-founder of Danforth Advisors, discusses the banner year biotech IPOs had in 2020, the drive behind that boom, and what the future of industry IPOs might look like.